Nautilus Biotechnology, Inc. 10-Q

ITEM 5. OTHER INFORMATION None. 74 ITEM 6. EXHIBITS Exhibit Number Description 3.1 Certificate of Incorporation of Nautilus Biotechnology, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 10, 2021) 3.2 Amended and Restated Bylaws of Nautilus Biotechnology, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.1 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Sujal Patel, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10 - Q filed with the SEC on August 2 , 202 3 ) 10.2 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Parag Mallick, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.3 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Anna Mowry, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.4 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Nick Nelson, dated of as July 31, 2023 (incorporated by reference to Exhibit 10. 4 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.5 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Gwen Weld, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 5 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.6 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Mary Godwin, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 6 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.7 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Subra Sankar, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 7 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.8 + Amended and Restated Confirmatory Employment Letter between Nautilus Biotechnology, Inc. and Matthew Murphy, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 8 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.9 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Sujal Patel, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 9 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.10 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Parag Mallick, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 0 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.11 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Anna Mowry, dated as of July 31, 2023 (incorporated by reference to Exhibit 10. 1 1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.12 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Nick Nelson, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.13 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Gwen Weld, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.14 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Mary Godwin, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 4 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.15 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Subra Sankar, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 5 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 10.16 + Amended and Restated Change in Control and Severance Agreement between Nautilus Biotechnology, Inc. and Matthew Murphy, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.1 6 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023) 75 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* † Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2* † Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover page Interactive Data File (embedded with the Inline XBRL document) __________________ * Filed herewith. + Indicates management contract or compensatory plan. † The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Nautilus Biotechnology, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. 76 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NAUTILUS BIOTECHNOLOGY, INC. Date: October 31, 2023 By: /s/ Sujal Patel Sujal Patel Chief Executive Officer (Principal Executive Officer) Date: October 31, 2023 By: /s/ Anna Mowry Anna Mowry Chief Financial Officer (Principal Financial and Accounting Officer) 77